Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNI-1493 for prevention of post-ERCP pancreatitis
NL-OMON23715Active, not recruiting
- Sponsor
- Cytokine PharmaSciences, Inc.
- Start
- Mar 2002
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) comparing CNI-1493 prophylaxis with Placebo (2 arms). Primary endpoint: Incidence of post-ERCP pancreatitis. Started Mar 2002; status: active, not recruiting.
02
Drugs
semapimod
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NL-OMON23715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23715.